King BBT, et al. - Researchers examined the prognostic value of postbiopsy pigmentation (PBP) in patients with cutaneous head and neck (H&N) melanoma. Three hundred patients who were undergoing sentinel lymph node biopsy (SLNB) for H&N melanoma (1998–2018) were retrospectively reviewed. They defined PBP as a visible remaining pigment at the scar or biopsy site that was documented on physical exam by both a medical oncologist and a surgeon at initial consultation. After wide local excision, PBP was noted in 34.3% (n=103) and microscopic residual disease was reported in 44.7% (n=134) on final pathology. Significantly shorter disease-free survival was observed for H&N melanoma patients with PBP. They recommend giving greater consideration to SLNB and closer postoperative surveillance in patients with PBP.